Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 468 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Aggressive Behavior Clear all

Conditions: Aggressive Behavior in Fragile X Syndome
Interventions: SRX246, Placebo; Drug
Lead sponsor: Azevan Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Sacramento, California • Chicago, Illinois • Cincinnati, Ohio

Conditions: Lymphoma
Interventions: filgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 80
States / cities: Anniston, Alabama • La Jolla, California • Los Angeles, California + 60 more

Conditions: Lymphoma
Interventions: filgrastim, rituximab, cisplatin, cytarabine, methylprednisolone, pixantrone dimaleate, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Theradex; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 28
States / cities: Tucson, Arizona • Duarte, California • Los Angeles, California + 23 more

Conditions: Prostate Cancer
Interventions: Questionnaires, Saliva Samples, Tumor Tissue; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 20 Years and older · Male only
Enrollment: 592 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
Interventions: cetuximab, laboratory biomarker analysis; Biological · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Aggressive Non-Hodgkin Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Plasma Cell Myeloma, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Waldenstrom Macroglobulinemia
Interventions: Total-Body Irradiation, Fludarabine Phosphate, Mycophenolate Mofetil, Cyclosporine, Peripheral Blood Stem Cell Transplantation; Procedure · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 6
States / cities: Medford, Oregon • Salt Lake City, Utah • Seattle, Washington + 1 more

Conditions: Schizophrenia
Interventions: Risperidone, divalproex; Drug
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Anger, Aggression
Interventions: Relaxation training plus RAGE-Control, Relaxation training plus Sham Videogame; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 7 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Soft Tissue Sarcoma
Interventions: [Ac 225]RTX-2358, [Cu64]LNTH-1363S; Drug · Diagnostic Test
Lead sponsor: Ratio Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 5
States / cities: Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more

Conditions: Non-Hodgkin Lymphoma
Interventions: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 22
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 19 more

Conditions: AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage I Grade 3 Follicular Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, HIV Infection, Plasmablastic Lymphoma, Primary Effusion Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma
Interventions: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Pharmacological Study, Prednisone, Rituximab, Vincristine Sulfate, Vorinostat; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 35
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more

Conditions: Impulsive Aggression
Interventions: Not listed
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 8 Years to 12 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Impulsive Aggression Comorbid With ADHD
Interventions: SPN-810, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 27
States / cities: Dothan, Alabama • Los Angeles, California • Santa Ana, California + 24 more

Conditions: Anger, Aggression
Interventions: ACT, ACT with RAGE-Control; Behavioral
Lead sponsor: Gonzalez-Heydrich, Joseph, M.D.; Individual
Eligibility: 10 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lymphoma
Interventions: BI 2536; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Omaha, Nebraska • Rochester, New York + 1 more

Conditions: Problematic Behavior in Children
Interventions: Not listed
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 8 Years to 18 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Brain Injury, Aggression
Interventions: Amantadine Hydrochloride, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 16 Years to 75 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Indianapolis, Indiana • Boston, Massachusetts • Charlotte, North Carolina + 3 more

Conditions: Aggression Childhood, Bullying Victimization, Social Behavior
Interventions: Universal, classroom-based, Bullying and Aggression Prevention Program; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 8 Years and older
Enrollment: 1,008 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Domestic Violence
Interventions: Fluoxetine; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Aggression, Self-injurious Behavior
Interventions: Trad FCT, Mult FCT, Mult FCT + Stimulus Fading; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 3 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: Aggression
Interventions: CBI, NUT; Behavioral · Dietary Supplement
Lead sponsor: University of Pennsylvania; Other
Eligibility: 11 Years to 12 Years
Enrollment: 335 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Aggression
Interventions: Psychotherapy; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue, Lymphoma, Small Lymphocytic, Waldenstrom Macroglobulinemia, Mantle-Cell Lymphoma
Interventions: Lenalidomide, Dexamethasone, Rituximab; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Adolescent, Bullying, Technology, Mental Health
Interventions: STAC-T; Behavioral
Lead sponsor: Klein Buendel, Inc.; Industry
Eligibility: 11 Years and older
Enrollment: 613 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Boise, Idaho • University, Mississippi

Search by objective public record fields.

Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse

Biobank for African American Prostate Cancer Research in Florida

Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer

Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility

RAGE-Control: Teaching Emotional Self-regulation Through Videogame Play

Actinium Therapy for Late-stage Aggressive Sarcomas

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors

A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

Anger Control Therapy (ACT) With RAGE-Control: An Outpatient Videogame-assisted Therapy for the Treatment of Anger

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Assessment of Bullying in Children

Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study

Examining the Efficacy of the PRAISE With Coaching Program

Effect of Fluoxetine (Prozac) on Domestic Violence

Refinements of Functional Communication Training

Healthy Brains & Behavior: Understanding and Treating Youth Aggression

Cognitive Behavioral Aggression Treatment

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

Online Bullying Bystander Intervention for Middle Schools Phase II